WO1992017446A3 - Pyridazinone acetic acids aldose reductase inhibitors - Google Patents

Pyridazinone acetic acids aldose reductase inhibitors Download PDF

Info

Publication number
WO1992017446A3
WO1992017446A3 PCT/US1992/001603 US9201603W WO9217446A3 WO 1992017446 A3 WO1992017446 A3 WO 1992017446A3 US 9201603 W US9201603 W US 9201603W WO 9217446 A3 WO9217446 A3 WO 9217446A3
Authority
WO
WIPO (PCT)
Prior art keywords
aldose reductase
phenyl
reductase inhibitors
acetic acids
oxadiazol
Prior art date
Application number
PCT/US1992/001603
Other languages
French (fr)
Other versions
WO1992017446A2 (en
Inventor
Banavara L Mylari
William J Zembrowski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority to CS923870A priority Critical patent/CZ387092A3/en
Priority to AU17796/92A priority patent/AU658887B2/en
Priority to BR9205810A priority patent/BR9205810A/en
Publication of WO1992017446A2 publication Critical patent/WO1992017446A2/en
Publication of WO1992017446A3 publication Critical patent/WO1992017446A3/en
Priority to FI934222A priority patent/FI934222A0/en
Priority to NO93933446A priority patent/NO933446L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds having aldose reductase inhibitory activity of formula (I) wherein X CH2, CH2CH2, -CHCH3, (a); Y=O or S; R1 is an optionally substituted phenyl, benzothiazol-2-yl, benzoxazol-2-yl, benzofuran-2-yl, benzothiophen-2-yl, thiazolopyridin-2-yl, oxazolopyridin-2-yl, 3-phenyl 1,2,4-oxadiazol-5-yl, and 5-phenyl-1,2,4-oxadiazol-3-yl wherein said substituted groups are substituted with one or more and preferably two substituents that are independently selected from fluorine, chlorine, bromine, methyl, and trifluoromethyl; R?2 and R3¿ are independently selected from hydrogen, fluorine, chlorine, bromine, (C¿1?-C4) alkyl, methyl (C1-C4) alkylthio, (C1-C4) alkoxy and trifluoromethyl or R?2 and R3¿ taken together with the carbons to which they are attached form a group W, wherein W is (b) or (c) wherein p is 1 or 2 and U?1 and U2¿ are independently CH¿2?, O or S with the proviso that both U?1 and U2¿ are not O or S; R4 is hydrogen or a prodrug group; or a pharmaceutically acceptable salt thereof.
PCT/US1992/001603 1991-03-28 1992-03-09 Pyridazinone acetic acids aldose reductase inhibitors WO1992017446A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CS923870A CZ387092A3 (en) 1991-03-28 1992-03-09 Pyridazinoacetic acids, their derivatives, process of their preparation and use
AU17796/92A AU658887B2 (en) 1991-03-28 1992-03-09 Pyridazinone acetic acids as aldose reductase inhibitors
BR9205810A BR9205810A (en) 1991-03-28 1992-03-09 Pyridazinone Acetic Acids
FI934222A FI934222A0 (en) 1991-03-28 1993-09-27 PYRIDAZINONAETTIKSYROR
NO93933446A NO933446L (en) 1991-03-28 1993-09-27 Pyridazinone acetic acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67691991A 1991-03-28 1991-03-28
US676,919 1991-03-28

Publications (2)

Publication Number Publication Date
WO1992017446A2 WO1992017446A2 (en) 1992-10-15
WO1992017446A3 true WO1992017446A3 (en) 1992-11-26

Family

ID=24716565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/001603 WO1992017446A2 (en) 1991-03-28 1992-03-09 Pyridazinone acetic acids aldose reductase inhibitors

Country Status (19)

Country Link
EP (1) EP0582643A1 (en)
JP (1) JPH06500793A (en)
CN (1) CN1065269A (en)
AU (1) AU658887B2 (en)
BR (1) BR9205810A (en)
CA (1) CA2107104A1 (en)
CZ (1) CZ387092A3 (en)
DE (1) DE9290035U1 (en)
FI (1) FI934222A0 (en)
HU (1) HUT67836A (en)
IE (1) IE920979A1 (en)
IL (1) IL101325A0 (en)
MX (1) MX9201414A (en)
NZ (1) NZ242152A (en)
PT (1) PT100301A (en)
TW (1) TW207998B (en)
WO (1) WO1992017446A2 (en)
YU (1) YU30392A (en)
ZA (1) ZA922238B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2240657T3 (en) 2001-02-28 2005-10-16 Pfizer Products Inc. SULFONILPIRIDAZINONA COMPOUNDS USEFUL AS INHIBITORS OF ALDOSA REDUCTASA.
SE0100873D0 (en) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
IL156462A0 (en) 2001-03-30 2004-01-04 Pfizer Prod Inc Pyridazinone aldose reductase inhibitors
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
CN111617072B (en) * 2019-02-27 2023-06-20 苏州凯祥生物科技有限公司 Hyperuricemia medicine composition and medicine for treating hyperuricemia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295051A2 (en) * 1987-06-09 1988-12-14 Pfizer Inc. Preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
FR2647676A1 (en) * 1989-06-05 1990-12-07 Union Pharma Scient Appl New pyridazinone derivatives, processes for preparing them and medicaments containing them which are useful, in particular, as aldose reductase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295051A2 (en) * 1987-06-09 1988-12-14 Pfizer Inc. Preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
FR2647676A1 (en) * 1989-06-05 1990-12-07 Union Pharma Scient Appl New pyridazinone derivatives, processes for preparing them and medicaments containing them which are useful, in particular, as aldose reductase inhibitors

Also Published As

Publication number Publication date
PT100301A (en) 1993-06-30
IL101325A0 (en) 1992-11-15
WO1992017446A2 (en) 1992-10-15
AU658887B2 (en) 1995-05-04
CZ387092A3 (en) 1994-02-16
MX9201414A (en) 1992-10-01
TW207998B (en) 1993-06-21
HUT67836A (en) 1995-05-29
CA2107104A1 (en) 1992-09-29
ZA922238B (en) 1993-09-27
BR9205810A (en) 1994-06-28
HU9302728D0 (en) 1993-12-28
IE920979A1 (en) 1992-10-07
AU1779692A (en) 1992-11-02
YU30392A (en) 1994-11-15
NZ242152A (en) 1994-07-26
CN1065269A (en) 1992-10-14
FI934222A (en) 1993-09-27
EP0582643A1 (en) 1994-02-16
DE9290035U1 (en) 1993-11-18
JPH06500793A (en) 1994-01-27
FI934222A0 (en) 1993-09-27

Similar Documents

Publication Publication Date Title
IL104614A (en) 4-benzoylisoxazole derivatives and herbicidal compositions comprising them
CA2299355A1 (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
DK0771794T3 (en) Oxygen-containing heterocyclic compounds
YU49122B (en) Substituted benzylaminopiperidine compounds
EP1642880A4 (en) Hsp90 family protein inhibitors
IE811085L (en) Pyridoxine derivatives
YU18999A (en) Substituted tricyclics
AU8240391A (en) Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes, 3-aminochromanes, and 3-aminothiochromanes
WO1992017446A3 (en) Pyridazinone acetic acids aldose reductase inhibitors
NO175254C (en) Analogous procedure for the preparation of therapeutically active derivatives of N-sulfonylindoline
YU52498A (en) USE OF 2-ARYLBENZEN (b) THIOPHENE FOR MEDICAMENT PREPARATION
AR042404A2 (en) COMPOUNDS DERIVED FROM ANILINA
MY104955A (en) Pyrroloquinoline and pyrrolophemothiazine carboxamides and related compounds.
AU5779380A (en) Allethrolone derivatives
HUP0002075A2 (en) Fungicidal mixtures
ES8201962A1 (en) Novel 1,1,3,5-substituted biuret compound and a pharmaceutical composition containing the same
ATE340155T1 (en) MEDICAL USES OF PHENYLAL CANOLS AND DERIVATIVES THEREOF
JPS57131772A (en) Novel cyclopropylmethylpiperazines and manufacture
CA2209313A1 (en) Heterocycle-fused thiazole derivatives
JPS6429367A (en) 2-amino-5-hydroxy-4-pyrimidone
NO933446L (en) Pyridazinone acetic acids
ES2151223T3 (en) TRIAZOLIC ANTIFUNGAL AGENTS.
AU9116791A (en) Antidoting herbicidal 3-isoxazolidinone compounds
CA2317691A1 (en) Triazole derivatives having antifungal activity
DK1027055T3 (en) 3-carboalkoxy-2,3-dihydro-1H-phenothiazin-4 (10H) -one derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CS DE FI HU JP KR NO PL RU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CS DE FI HU JP KR NO PL RU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

WWE Wipo information: entry into national phase

Ref document number: PV1992-3870

Country of ref document: CZ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
EX32 Extension under rule 32 effected after completion of technical preparation for international publication
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
WWE Wipo information: entry into national phase

Ref document number: 1992910955

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2107104

Country of ref document: CA

Ref document number: 934222

Country of ref document: FI

ENP Entry into the national phase

Ref document number: 1993 122495

Country of ref document: US

Date of ref document: 19930928

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: PV1992-3870

Country of ref document: CZ

Ref document number: 1992910955

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: PV1992-3870

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1992910955

Country of ref document: EP